Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Non-Current Deffered Revenue (2019 - 2020)

Oric Pharmaceuticals filings provide 2 years of Non-Current Deffered Revenue readings, the most recent being $219000.0 for Q4 2020.

  • Quarterly Non-Current Deffered Revenue fell 71.37% to $219000.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $219000.0 through Dec 2020, down 71.37% year-over-year, with the annual reading at $219000.0 for FY2020, 71.37% down from the prior year.
  • Non-Current Deffered Revenue hit $219000.0 in Q4 2020 for Oric Pharmaceuticals, down from $359000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $765000.0 in Q4 2019 and bottomed at $219000.0 in Q4 2020.